Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study
Hepatology Research2017Vol. 48(1), pp. 69–77
Citations Over TimeTop 10% of 2017 papers
Jeremy Cobbold, Stephen R. Atkinson, Julian R. Marchesi, Ann Smith, Sann N. Wai, J Stove, Fariba Shojaee‐Moradie, Nicola Jackson, A. Margot Umpleby, Julie Fitzpatrick, E. Louise Thomas, Jimmy D. Bell, Elaine Holmes, Simon D. Taylor‐Robinson, Robert Goldin, Michael Yee, Quentin M. Anstee, Mark Thursz
Abstract
These data do not indicate a beneficial effect of rifaximin in patients with NASH.
Related Papers
- → Sa1567 MRI INTENSITY PATTERNS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND ALCOHOLIC STEATOHEPATITIS(2020)1 cited
- → Role of mutations of HFE gene in non-alcoholic steatohepatitis and alcoholic liver disease(2002)
- Application of rifaximin in digestive tract diseases(2012)
- [Comparison of the immune response in patients with alcoholic liver disease and non-alcoholic steatohepatitis].(2011)
- Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease(2007)